Bridging the Survival Gap: The Fight Against Childhood Cancer

By Danélia Botes

February 15, 2024

Introduction:

On International Childhood Cancer Day 2024, we take this opportunity to highlight the significant contribution that parents, family physicians, and paediatricians make to the early detection of cancers in children. On a daily basis, childhood cancer affects some of the most vulnerable communities. Globally the focus is shifting more and more towards the importance of early detection. The survival rates of children with cancer vary dramatically between high-income and low- to middle-income countries.

The Global Childhood Cancer Burden

Every day, over 1000 children worldwide are diagnosed with cancer. In high-income countries, advancements in medical technology have led to survival rates exceeding 80%. However, in some low- and middle-income countries, only about 20% of children diagnosed with cancer survive. Not only does the enhancement of cancer care for children present a significant opportunity to save lives and alleviate suffering, but it also has the potential to accelerate the development of a cancer control program that is more inclusive and to demonstrate success in the larger child health and noncommunicable disease (NCD) agenda.

The WHO’s Global Initiative for Childhood Cancer Survival Gap

In 2018, the World Health Organisation (WHO) together with St. Jude Children’s Research Hospital and other global partners launched the Global Initiative for Childhood Cancer (GICC). This initiative aims to bridge the childhood cancer survival gap by 2030. Ensuring at least 60% of children with cancer worldwide survive their diagnosis. Through the utilisation of the CureAll framework as the coordinated operational strategy, the Initiative functions to bring together stakeholders from a variety of sectors in order to achieve a common objective.

The Role and Impact of Parents

Parents play a critical role in early detection of childhood cancer. Early detection requires identification of signs and symptoms in young children who may not be able to express them. Parents must be aware of these signals to ensure timely diagnosis and staging. Knowing the early signs and symptoms of specific cancers and being vigilant could potentially save a child’s life.

Figure 1: Percentage of countries with early detection programmes/guidelines and referral
system for suspected childhood cancer cases, by World Bank income group, 2019

 

The Fight Against Childhood Cancers

Many low- and middle-income countries still struggle with early diagnosis and treatment of childhood cancer. Recent data shows that only 20% of nations globally report having early detection programs or guidelines to enhance early diagnosis of childhood cancer symptoms at primary care level (Figure 1). There is a clear need for a more accessible and well-defined referral system for suspected childhood cancer cases. This system should span from primary care to intermediate and tertiary care. This system, unfortunately, is only in place in one third of the globe.

Conclusion:

International Childhood Cancer Day is an opportunity for us all to contribute to a future where every child, irrespective of their birthplace, has the chance to live a healthy life. It’s not just about raising awareness; it’s a call to action for everyone to join the fight against childhood cancer. There is no way to understate the importance of raising awareness and educating people, particularly parents, about childhood cancer.

Reference url

Recent Posts

Opdivo lung cancer approval
           

FDA’s Opdivo Lung Cancer Approval

🚀 The FDA has made a groundbreaking move by approving Opdivo (nivolumab) as a neoadjuvant treatment for resectable non-small cell lung cancer (NSCLC). This new regimen, combining Opdivo with platinum-doublet chemotherapy, aims to enhance patient outcomes pre- and post-surgery. With promising results from recent clinical trials, it’s a significant step forward in cancer care!

Learn more about this advancement and its implications for patients.

#SyenzaNews #CancerCare #FDAApproval

Mental Healthcare for Youth
                   

Mental Healthcare for Youth: Addressing Substance Use and Chronic Conditions

🌍🧠 Today, on World Mental Health Day, let’s focus on the mental well-being of our youth. With one in seven adolescents experiencing mental disorders, it’s crucial to address the challenges they face in accessing care. Innovative solutions like telemedicine and school-based programmes offer hope.
Let’s advocate for policies that prioritise youth mental health. Together, we can create a supportive environment for young people to thrive. 🌟
#SyenzaNews #WorldMentalHealthDay #YouthMentalHealth #MentalHealthAwareness

elacestrant breast cancer therapy
         

NICE Collaborates with Menarini to Evaluate Elacestrant Breast Cancer Treatment

🔍 The conversation surrounding elacestrant for advanced breast cancer is gaining momentum! The National Institute for Health and Care Excellence (NICE) is working closely with Menarini Stemline to address critical uncertainties in evidence. As this drug aims to tackle oestrogen receptor-positive, HER2-negative breast cancers with activating ESR1 mutations, public consultation is underway until 22 October 2024.

Stay informed about potential advancements in treatment options and the importance of collaboration in healthcare.

#SyenzaNews #BreastCancer #HealthcareInnovation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

JOIN NEWSLETTER




SERVICES

© 2024 Syenza™. All rights reserved.